Laboratori de Fisiologia Molecular, Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, C/ Dr. Aiguader, 88, 08003, Barcelona, Spain.
Neuropediatric Department, Institut de Recerca Sant Joan de Déu, Hospital Sant Joan de Déu, 08950, Barcelona, Spain.
Pflugers Arch. 2020 Jul;472(7):791-809. doi: 10.1007/s00424-020-02396-z. Epub 2020 May 26.
Human mutations in the CACNA1A gene that encodes the pore-forming α subunit of the voltage-gated Ca2.1 (P/Q-type) Ca channel cause multiple neurological disorders including sporadic and familial hemiplegic migraine, as well as cerebellar pathologies such as episodic ataxia, progressive ataxia, and early-onset cerebellar syndrome consistent with the definition of congenital ataxia (CA), with presentation before the age of 2 years. Such a pathological role is in accordance with the physiological relevance of Ca2.1 in neuronal tissue, especially in the cerebellum. This review deals with the report of the main clinical features defining CA, along with the presentation of an increasing number of CACNA1A genetic variants linked to this severe cerebellar disorder in the context of Ca homeostasis alteration. Moreover, the review describes each pathological mutation according to structural location and known molecular and cellular functional effects in both heterologous expression systems and animal models. In view of this information in correlation with the clinical phenotype, we take into consideration different pathomechanisms underlying the observed motor dysfunction in CA patients carrying CACNA1A mutations. Present therapeutic management in CA and options for the development of future personalized treatment based on Ca2.1 dysfunction are also discussed.
人类 CACNA1A 基因突变,该基因编码电压门控 Ca2.1(P/Q 型)Ca 通道的孔形成α亚基,导致多种神经紊乱,包括散发性和家族性偏瘫性偏头痛,以及小脑病变,如发作性共济失调、进行性共济失调和早发性小脑综合征,符合先天性共济失调(CA)的定义,发病年龄在 2 岁之前。这种病理作用与 Ca2.1 在神经元组织中的生理相关性一致,尤其是在小脑。本文综述了主要的临床特征定义 CA 的报告,以及越来越多的 CACNA1A 基因突变与 Ca 稳态改变相关的这种严重小脑紊乱的相关性。此外,该综述根据结构位置以及在异源表达系统和动物模型中的已知分子和细胞功能效应描述了每个病理突变。鉴于这些信息与临床表型的相关性,我们考虑了携带 CACNA1A 突变的 CA 患者观察到的运动功能障碍的不同病理机制。还讨论了 CA 的目前治疗管理以及基于 Ca2.1 功能障碍的未来个性化治疗的选择。